5/3
07:00 am
gthx
G1 Therapeutics First Quarter 2024 Earnings: Revenues Disappoint [Yahoo! Finance]
Low
Report
G1 Therapeutics First Quarter 2024 Earnings: Revenues Disappoint [Yahoo! Finance]
5/2
02:07 pm
gthx
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Low
Report
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
5/1
05:50 pm
gthx
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/1
12:34 pm
gthx
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Medium
Report
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
5/1
08:32 am
gthx
G1 Therapeutics and Pepper Bio sign license agreement for lerociclib [Seeking Alpha]
Medium
Report
G1 Therapeutics and Pepper Bio sign license agreement for lerociclib [Seeking Alpha]
5/1
06:42 am
gthx
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights [Yahoo! Finance]
Medium
Report
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights [Yahoo! Finance]
5/1
06:30 am
gthx
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib [Yahoo! Finance]
Medium
Report
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib [Yahoo! Finance]
5/1
06:30 am
gthx
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
High
Report
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
5/1
06:25 am
gthx
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
Medium
Report
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
4/19
11:19 am
gthx
G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To Profit [Yahoo! Finance]
Low
Report
G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To Profit [Yahoo! Finance]
4/17
09:00 am
gthx
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
Low
Report
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
4/12
08:01 am
gthx
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Low
Report
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
4/4
10:34 am
gthx
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
Low
Report
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
4/4
10:30 am
gthx
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Low
Report
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
4/1
04:20 pm
gthx
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/22
05:56 pm
gthx
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape [Seeking Alpha]
Medium
Report
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape [Seeking Alpha]
3/1
04:20 pm
gthx
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/29
10:38 am
gthx
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/28
05:12 pm
gthx
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock, up previously from $4.00.
Low
Report
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock, up previously from $4.00.
2/28
12:14 pm
gthx
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Medium
Report
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
2/28
07:10 am
gthx
G1 Therapeutics Inc (GTHX) Reports Strong Revenue Growth in 2023 [Yahoo! Finance]
High
Report
G1 Therapeutics Inc (GTHX) Reports Strong Revenue Growth in 2023 [Yahoo! Finance]
2/28
06:38 am
gthx
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights [Yahoo! Finance]
High
Report
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights [Yahoo! Finance]
2/28
06:30 am
gthx
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
High
Report
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
2/27
08:43 am
gthx
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference [Yahoo! Finance]
Low
Report
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference [Yahoo! Finance]
2/27
08:30 am
gthx
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
Medium
Report
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference